A Phase 3 interventional study of ADX-102 Ophthalmic Solution (0.5%) and Vehicle of ADX-102 Ophthalmic Solution in Non-infectious Anterior Uveitis, sponsored by Aldeyra Therapeutics, Inc.. Completed at 27 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-02-10.
Sponsored by Aldeyra Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Uveitis, Anterior with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Uveitis, Anterior · United States.
Among the 30 studies in Uveitis, Anterior with a site in United States, this one is the 7th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2017, is one of 9 in phase 3, and was the 20th registered.
56 studies on the registry are indexed under Uveitis, Anterior; 9 are open to participants now.
Browse Uveitis, Anterior studies →5 of the 30 studies in Uveitis, Anterior with a site in United States are open now. Recruiting first, the newest first:
Oregon Health and Science University · Sites in United States
Ages 5–85 · Healthy volunteers
Massachusetts Eye Research and Surgery Institution · Sites in United States
Ages 18+ · Healthy volunteers
University of California, San Francisco · Sites in United States, Taiwan, Thailand
Ages 18+ · Healthy volunteers
Nisha Acharya · Sites in United States, Italy, United Kingdom
Ages 2+
CARE ARTHRITIS LTD. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Uveitis, Anterior studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 11 · Phase 4 4
First in 2005; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 123 is above the median of 50 across 45 interventional studies indexed under Uveitis, Anterior.
Median enrollment 40 across the 27 interventional studies, 50 across the 3 observational. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 30 have an industry lead sponsor. The 10 most frequent:
Aldeyra Therapeutics, Inc. is the lead sponsor of 35 studies on the registry; 1 is open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 25 (86%) have results posted.
Aldeyra Therapeutics, Inc. has 2 studies filed under Uveitis, Anterior — fewer than ten, so there is no comparison to draw.
2 of the studies in Uveitis, Anterior with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07285070Novaliq GmbHTacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis | 2026-12 |
| NCT07018206CARE ARTHRITIS LTD.Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in Uveitis, Anterior with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 3, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in Subjects with non-infectious anterior-uveitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ADX-102 Ophthalmic Solution (0.5%)
Drug: Vehicle of ADX-102 Ophthalmic Solution
ADX-102 Ophthalmic Solution (0.5%) administered for approximately four weeks.
Also known as: Reproxalap
Vehicle of ADX-102 Ophthalmic Solution administered for approximately four weeks.
Also known as: Vehicle of Reproxlap
Number of Subjects Who Meet Time to Clearance of Anterior Chamber Cells
Time to clearance of anterior chamber cells was defined as the time from initiation of study drug to when a cell count of 0 was achieved and maintained (without cell count increases to \>0) to Week 4 and without rescue or discontinuation due to rescue prior to Week 4. Anterior chamber cell count is the number of cells visible within the anterior chamber of the eye, measured using a slit lamp and following SUN (Standardization of Uveitis Nomenclature) where a cell count \<1 is Grade 0 (absent) and a cell count of \>50 is Grade 4+ (severe).
Time frame: The efficacy assessment period was 4 weeks; baseline was defined as Day 1.
| Milestone | ADX-102 Ophthalmic Solution (0.5%) | Vehicle Ophthalmic Solution |
|---|---|---|
| Started | 61 | 62 |
| Completed | 37 | 33 |
| Not completed | 24 | 29 |
Time to clearance of anterior chamber cells was defined as the time from initiation of study drug to when a cell count of 0 was achieved and maintained (without cell count increases to \>0) to Week 4 and without rescue or discontinuation due to rescue prior to Week 4. Anterior chamber cell count is the number of cells visible within the anterior chamber of the eye, measured using a slit lamp and following SUN (Standardization of Uveitis Nomenclature) where a cell count \<1 is Grade 0 (absent) and a cell count of \>50 is Grade 4+ (severe).
| Subjects | ADX-102 Ophthalmic Solution (0.5%) | Vehicle Ophthalmic Solution |
|---|---|---|
| Number of Subjects Who Meet Time to Clearance of Anterior Chamber Cells | 25 | 24 |
Time to clearance of anterior chamber cells was defined as the time from initiation of study drug to when a cell count of 0 was achieved and maintained (without cell count increases to \>0) to Week 4 and without rescue or discontinuation due to rescue prior to Week 4. Anterior chamber cell count is the number of cells visible within the anterior chamber of the eye, measured using a slit lamp and following SUN (Standardization of Uveitis Nomenclature) where a cell count \<1 is Grade 0 (absent) and a cell count of \>50 is Grade 4+ (severe).
| Subjects | ADX-102 Ophthalmic Solution (0.5%) | Vehicle Ophthalmic Solution |
|---|---|---|
| Number of Subjects With Time to Clearance of Anterior Chamber Cells in Grade 1+ or Grade 2+ Subjects With a Baseline Anterior Chamber Cell Count > 10 | 13 | 6 |
Collected over The period of time over which adverse events were collected for each subject in the clinical trial was approximately five weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ADX-102 Ophthalmic Solution (0.5%) | 0/61 (0%) | 1/61 (1.6%) | 36/61 (59%) |
| Vehicle Ophthalmic Solution | 0/62 (0%) | 2/62 (3.2%) | 31/62 (50%) |
| Event | ADX-102 Ophthalmic Solution (0.5%) | Vehicle Ophthalmic Solution |
|---|---|---|
| Suicide AttemptPsychiatric disorders | 1/61 | 0/62 |
| Visual acuity reducedEye disorders | 0/61 | 1/62 |
| SyncopeNervous system disorders | 0/61 | 1/62 |
| Event | ADX-102 Ophthalmic Solution (0.5%) | Vehicle Ophthalmic Solution |
|---|---|---|
| General Disorders and Administration Site ConditionsGeneral disorders | 13/61 | 0/62 |
| UveitisEye disorders | 7/61 | 7/62 |
| Eye painEye disorders | 7/61 | 7/62 |
| Visual acuity reducedEye disorders | 3/61 | 6/62 |
| IridocyclitisEye disorders | 4/61 | 3/62 |
| Eye inflammationEye disorders | 2/61 | 4/62 |
| Vitreous floatersEye disorders | 0/61 | 4/62 |
| Age, Continuous(years) | ADX-102 Ophthalmic Solution (0.5%) | Vehicle Ophthalmic Solution | Total |
|---|---|---|---|
| Mean | 45.3 ± 15.8 | 47.8 ± 17.9 | 46.5 ± 16.9 |
| Sex: Female, Male(Participants) | ADX-102 Ophthalmic Solution (0.5%) | Vehicle Ophthalmic Solution | Total |
|---|---|---|---|
| Female | 34 | 41 | 75 |
| Male | 27 | 21 | 48 |
| Ethnicity (NIH/OMB)(Participants) | ADX-102 Ophthalmic Solution (0.5%) | Vehicle Ophthalmic Solution | Total |
|---|---|---|---|
| Hispanic or Latino | 27 | 22 | 49 |
| Not Hispanic or Latino | 34 | 40 | 74 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | ADX-102 Ophthalmic Solution (0.5%) | Vehicle Ophthalmic Solution | Total |
|---|---|---|---|
| White | 50 | 48 | 98 |
| Black or African American | 8 | 10 | 18 |
| Asian | 0 | 1 | 1 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Unknown | 1 | 0 | 1 |
| Other | 1 | 3 | 4 |
| Region of Enrollment(participants) | ADX-102 Ophthalmic Solution (0.5%) | Vehicle Ophthalmic Solution | Total |
|---|---|---|---|
| United States | 61 | 62 | 123 |
| Height(centimeters) | ADX-102 Ophthalmic Solution (0.5%) | Vehicle Ophthalmic Solution | Total |
|---|---|---|---|
| Mean | 167.09 ± 9.72 | 169.30 ± 9.57 | 168.2 ± 9.67 |
| Weight(kilograms) | ADX-102 Ophthalmic Solution (0.5%) | Vehicle Ophthalmic Solution | Total |
|---|---|---|---|
| Mean | 85.95 ± 20.62 | 85.45 ± 21.98 | 85.70 ± 21.23 |
| Subjects with Bilateral Uveitis(participants) | ADX-102 Ophthalmic Solution (0.5%) | Vehicle Ophthalmic Solution | Total |
|---|---|---|---|
| Right Eye | 25 | 23 | 48 |
| Left Eye | 30 | 34 | 64 |
| Both Eyes | 6 | 5 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2017 to primary completion in Apr 2019, 23 months.
Results were first posted in Feb 2025, 5 years 9 months after primary completion. A results delay was requested in May 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Reproxalap